Tolerance of Benznidazole in a United States Chagas Disease Clinic | Zendy

David A. Miller | Zendy; Salvador Hernández | Zendy; Lissette Rodríguez de Armas | Zendy; Samantha J. Eells | Zendy; Marcello Traina | Zendy; Loren G. Miller | Zendy; Sheba Meymandi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tolerance of Benznidazole in a United States Chagas Disease Clinic

Author(s) -

David A. Miller,

Salvador Hernández,

Lissette Rodríguez de Armas,

Samantha J. Eells,

Marcello Traina,

Loren G. Miller,

Sheba Meymandi

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ005

Subject(s) - benznidazole , medicine , chagas disease , disease , observational study , trypanosoma cruzi , immunology , parasite hosting , world wide web , computer science

The US-based Center of Excellence for Chagas Disease performed an observational study on the safety and tolerance of benznidazole 5 mg/kg/day for 60 days in 30 adults with chronic Chagas disease. The side-effect profile was suboptimal, including 5 cases of debilitating neuropathy and an unusually high angioedema rate.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research